Using biomarkers to predict clinical outcomes in multiple sclerosis. Issue 4 (26th June 2019)

• Record Type: Journal Article
• Authors: Castle, Daniel; Wynford-Thomas, Ray; Loveless, Sam; Bentley, Emily; Howell, Owain W; Tallantyre, Emma C
• Is Part Of: Practical neurology. Volume 19:Issue 4(2019)
• Page Start: 342
• Page End: 349
• Publication Date: 2019-06-26
• Subjects: multiple sclerosis (ms) -- biomarkers -- outcome -- neurofilament -- pathophysiology; Neurology -- Periodicals; 616.8005
• DOI: 10.1136/practneurol-2018-002000
• Languages: English
• ISSNs: 1474-7758

Abstract

Abstract : Long-term outcomes in multiple sclerosis (MS) are highly varied and treatment with disease-modifying therapies carries significant risks. Finding tissue biomarkers that can predict clinical outcomes would be valuable in individualising treatment decisions for people with MS. Several candidate biomarkers—reflecting inflammation, neurodegeneration and glial pathophysiology—show promise for predicting outcomes. However, many candidates still require validation in cohorts with long-term follow-up and evaluation for their independent contribution in predicting outcome when models are adjusted for known demographic, clinical and radiological predictors. Given the complexity of MS pathophysiology, heterogeneous panels comprising a combination of biomarkers that encompass the various aspects of neurodegenerative, glial and immune pathology seen in MS, may enhance future predictions of outcome.